2012;2012:9 pages
The clinical course of WD can vary in the type and severity of symptoms, but progressive liver disease is a common feature
Regular tracking during extended protocols should include periodic reassessment of laboratory parameters (glucose body function, liver and kidney function, lipid profile, complete blood count), growth factor levels (IGF-1, IGFBP-3, possibly growth hormone), body makeup and research-specific outcomes, and screening for possible adverse effects
On the other hand, L-arginine and L-NAME administration can affect the process partially, having no major influence on final outcome, lesions in the stomach or sphincters function
Professional monitoring ensures that dosages are adjusted safely and that your vital organs are functioning correctly throughout the process